Wolfgang Miesbach: What the Latest Gene Therapy Setbacks Mean for Haemophilia Care
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Another setback — and what it means.
Be Biopharma has terminated its Phase 1/2 BeCoMe-9 trial of BE-101, an autologous B-cell therapy for severe haemophilia B, after enrolling just 5 of 24 planned patients – a ‘strategic business decision’ not a safety issue.
BE-101 edited patients’ own B cells ex vivo to produce FIX, with stable activity and re-dosing potential.
It was one of the very few B-cell therapies so far.
This comes on top of:
- Pfizer cutting all funding and global rollout of its approved haemophilia B gene therapy Beqvez, citing limited interest from patients and physicians
- BioMarin withdrawing its haemophilia A gene therapy Roctavian after slow uptake and modest sales, despite regulatory success
So what does this mean for gene therapy in haemophilia?
Approval and elegant biology are not equivalent to real-world adoption.
Durability, re-dosing, eligibility, cost and system readiness are what decide.
Today’s ‘one-and-done’ liver-directed AAV approaches may stay niche while highly effective factor and non-factor prophylaxis remain widely available.
In my view, this is less a verdict against gene therapy than a call to align the next generation of trials and products with what truly matters to people with hemophilia: durable bleed protection, full reimbursement, and sustainable integration into care.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 22, 2026, 16:45Shivangi Harankhedkar: Gene Therapy and CRISPR Advances in Hemoglobinopathies
-
Jun 22, 2026, 16:39Vikram Sinai Talaulikar: Haematology and Female Hormone Health Intersect at Multiple Levels
-
Jun 22, 2026, 16:35Sehrish Chaudhary: Advancing Transfusion Medicine Through Global Collaboration at ISBT 2026
-
Jun 22, 2026, 15:54Ready to Build Your ISTH 2026 Schedule?
-
Jun 22, 2026, 15:26Suvro Sankha Datta: Advancing Transfusion Medicine Through the Establishment of a Red Cell Genotyping Facility
-
Jun 22, 2026, 15:08Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
-
Jun 22, 2026, 14:41Ilkin Aygun Soyalp: Novel Substrate Recognition Broadens the Biological Role of DPF-3
-
Jun 22, 2026, 14:29Swarnava Roy: Linking Angiotensin Signaling to Oxidative Stress and Organ Damage in Sickle Cell Anemia
-
Jun 22, 2026, 14:14Nicolò Vianini: New Evidence Confirms Bone Marrow as the Primary Site of Thrombopoiesis